Back to News
Jan 8, 2026 4:20 AM

Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis

LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd ("Engitix"), a biotech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a $25 million Series A extension financing, by Netherton Investments, a fund investing on behalf of Mike Platt, the co-founder and Managing Director of BlueCrest Capital Management.

Proceeds will be used to continue preclinical development across Engitix's proprietary ECM-targeted pipeline in solid tumors and fibrosis, and to further expand and apply Engitix's platform built on one of the largest proprietary ECM datasets in these diseases. Engitix leverages deep, high-resolution ECM ...